Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS
Open Access
- 10 July 2012
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 36 (5), 437-448
- https://doi.org/10.1111/j.1365-2036.2012.05208.x
Abstract
Background Patients with irritable bowel syndrome with diarrhoea (IBS-D) experience restriction in daily activities and decreased health-related quality of life (QOL). Aim To investigate effects of alosetron on patient-reported health-related QOL, satisfaction and productivity in women with severe IBS-D. Methods A total of 705 women (severe IBS-D, Rome II criteria) randomised to alosetron 0.5 mg QD, 1 mg QD, 1 mg BID, or placebo for 12 weeks were studied. IBSQOL, treatment satisfaction, daily activities, and lost workplace productivity (LWP) were evaluated at randomisation and Week 12. Results One or more doses of alosetron significantly improved all IBSQOL domains except for sexual function from baseline vs. placebo. The magnitude of IBSQOL changes was consistent with a clinically meaningful effect. Alosetron 0.5 mg QD and 1 mg BID significantly reduced IBS interference with social/leisure activities and LWP from baseline vs. placebo [social/leisure (mean +/- S.E.) days lost: -6.7 +/- 0.8, -7.0 +/- 0.9, P < 0.01; LWP (mean +/- S.E.) h lost: -11.0 +/- 3.3, -21.1 +/- 4.1, P < 0.05 respectively]. Significantly more patients treated with alosetron reported satisfaction vs. placebo. Improvements in IBSQOL, LWP, and treatment satisfaction significantly correlated with global improvement of IBS symptoms. The incidence of adverse events with alosetron was low with constipation being the most commonly reported event. A single case of ischaemic colitis occurred, in a patient receiving alosetron 0.5 mg QD. Conclusions In women with severe IBS-D, alosetron treatment, including 0.5 mg QD, resulted in statistically significant and clinically relevant improvements in health-related QOL, restriction of daily activities and treatment satisfaction over placebo. IBS symptom improvement corresponded with positive changes in IBSQOL, LWP and treatment satisfaction.Keywords
This publication has 36 references indexed in Scilit:
- Quality of Life in Patients With Irritable Bowel SyndromeJournal of Clinical Gastroenterology, 2011
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without ConstipationNew England Journal of Medicine, 2011
- International Survey of Patients With IBSJournal of Clinical Gastroenterology, 2009
- Self-Administered Cognitive Behavior Therapy for Moderate to Severe Irritable Bowel Syndrome: Clinical Efficacy, Tolerability, FeasibilityClinical Gastroenterology and Hepatology, 2008
- Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12-week trialsClinical Therapeutics, 2008
- Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsClinical Gastroenterology and Hepatology, 2008
- Irritable bowel syndrome and surgery: A multivariable analysis☆Gastroenterology, 2004
- The economic impact of irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2003
- A double‐blind, randomized, placebo‐controlled dose‐ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2000
- Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonistAlimentary Pharmacology & Therapeutics, 1999